Loading institutional data...
Loading institutional data...
Held by 455 of 5,944 reporting institutions (96th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $45M buybacks = $45M returned on -$233M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -30%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~0.3% on $1.5B of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-18
Nothing notable to watch.
Where each multiple sits in its own 8-yr range · 50th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 8-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | — | — | — | — | 40.3 | 39.2 | 35.5 |
| R&D | 56.0 | 40.3 | 52.3 | 70.4 | 83.2 | 65.1 | 47.1 | 37.1 |
| SG&A | 39.9 | 28.6 | 67.2 | 55.3 | 36.5 | 27.6 | 24.4 | 21.5 |
| Operating Income | -102.5 | -38.4 | -88.9 | -110.0 | -121.1 | -100.1 | -60.0 | -44.5 |
| Income Tax | 0.0 | -0.9 | 0.1 | 0.1 | 0.3 | 0.1 | 0.2 | -0.1 |
| Net Income | -93.8 | -35.3 | -85.9 | -103.0 | -145.6 | -85.0 | -59.1 | -42.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on GH: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $982.0M 100.0% | $739.0M 100.0% | $563.9M 100.0% | $449.5M 100.0% | $373.7M 100.0% | $286.7M 100.0% | $214.4M 100.0% | $90.6M 100.0% | $49.8M 100.0% | $25.2M 100.0% |
| Cost of Revenue | $349.0M 35.5% | $289.8M 39.2% | $227.1M 40.3% | — | — | — | — | — | — | — |
| Research & Development | $364.2M 37.1% | $347.8M 47.1% | $367.2M 65.1% | $373.8M 83.2% | $263.2M 70.4% | $149.9M 52.3% | $86.3M 40.3% | $50.7M 56.0% | $25.6M 51.3% | $10.9M 43.0% |
| Selling, General & Admin | $211.4M 21.5% | $180.1M 24.4% | $155.8M 27.6% | $164.0M 36.5% | $206.6M 55.3% | $192.8M 67.2% | $61.4M 28.6% | $36.2M 39.9% | $36.8M 73.8% | $9.9M 39.3% |
| Total Operating Expenses | $1.42B 144.5% | $1.18B 160.0% | $1.13B 200.1% | $993.9M 221.1% | $784.7M 210.0% | $541.7M 188.9% | $296.7M 138.4% | $183.6M 202.5% | $126.5M 253.7% | $69.1M 273.7% |
| Operating Income | -$437.2M -44.5% | -$443.6M -60.0% | -$564.7M -100.1% | -$544.4M -121.1% | -$411.0M -110.0% | -$254.9M -88.9% | -$82.4M -38.4% | -$92.9M -102.5% | -$76.6M -153.7% | -$43.8M -173.7% |
| Interest Expense | $3.9M 0.4% | $2.6M 0.3% | $2.6M 0.5% | $2.6M 0.6% | $2.6M 0.7% | $4.8M 1.7% | $1.2M 0.6% | $1.3M 1.4% | $2.7M 5.4% | $3.0M 12.0% |
| Interest & Investment Income | $34.1M 3.5% | $53.7M 7.3% | $35.4M 6.3% | $6.1M 1.4% | $3.9M 1.1% | $10.2M 3.5% | $13.7M 6.4% | $5.3M 5.8% | $2.2M 4.5% | $733K 2.9% |
| Other Income (Expense), net | -$10.5M -1.1% | -$42.6M -5.8% | $53.2M 9.4% | -$12.8M -2.8% | $25.2M 6.7% | $3.6M 1.3% | $88K 0.0% | $4.7M 5.2% | -$1.1M -2.1% | -$1K -0.0% |
| Pretax Income | -$417.5M -42.5% | -$435.1M -58.9% | -$478.8M -84.9% | -$653.4M -145.4% | -$384.5M -102.9% | -$245.9M -85.8% | -$69.7M -32.5% | -$84.2M -92.9% | -$83.2M -167.0% | -$46.1M -182.7% |
| Income Tax Expense | -$1.3M -0.1% | $1.3M 0.2% | $685K 0.1% | $1.1M 0.3% | $300K 0.1% | $379K 0.1% | -$1.9M -0.9% | $38K 0.0% | $7K 0.0% | $6K 0.0% |
| Net Income | -$416.3M -42.4% | -$436.4M -59.1% | -$479.4M -85.0% | -$654.6M -145.6% | -$384.8M -103.0% | -$246.3M -85.9% | -$75.7M -35.3% | -$85.1M -93.8% | -$83.2M -167.0% | -$46.1M -182.7% |
| Per Share | ||||||||||
| EPS (Basic) | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 | $-2.60 | $-0.84 | — | — | — |
| EPS (Diluted) | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 | $-2.60 | $-0.84 | — | — | — |
| Weighted Avg Shares (Basic) | 125.4M | 122.7M | 112.0M | 102.2M | 101.3M | 97.5M | 90.6M | — | — | — |
| Weighted Avg Shares (Diluted) | 125.4M | 122.7M | 112.0M | 102.2M | 101.3M | 97.5M | 90.6M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| GH | $23.4B | — | — | 23.9× | 32.9% | 64.5% | -42.4% | 419% | -29.6% | -3.8× | 455 |
Peers = companies sharing GH's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.